Cellectis Boosts Leadership with New CMO
Company Announcements

Cellectis Boosts Leadership with New CMO

Cellectis SA (CLLS) has released an update.

Cellectis SA, a clinical-stage biotech company, has just appointed Dr. Adrian Kilcoyne as the new Chief Medical Officer, strengthening its leadership in pioneering gene-editing and cell therapy technologies. Dr. Kilcoyne brings extensive experience from his previous roles at Celularity and Humanigen, aiming to advance Cellectis’ innovative CAR T-cell therapies. The company continues its mission to meet significant unmet medical needs with its promising product pipeline and experienced team.

For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCellectis S.A. Reports Q3 2024 Financial Results and Updates
TipRanks Auto-Generated NewsdeskCellectis SA Advances CAR T-cell Therapy for Solid Tumors
TheFlyCellectis price target lowered to $5 from $7 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App